Startseite Kongressberichte & Archiv 2021 ASCO Annual Meeting Haematological Malignancies Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Second-line bosutinib (BOS) for patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML): Final 10-year results of a phase 1/2 study.
Carlo Gambacorti-Passerini, Tim H. Brümmendorf, Dong-Wook Kim, et al.
The study authors conclude that the results are consistent with prior results of durable efficacy and manageable toxicity with 2nd-line bosutinib. They support long-term bosutinib use in chronic phase chronic myeloid leukemia after imatinib failure. Clinical trial information: NCT00261846 NCT01903733.
Phase II study of the IDH2-inhibitor enasidenib in patients with high-risk IDH2-mutated myelodysplastic syndromes (MDS).
Sangeetha Venugopal, Courtney Denton Dinardo, Koichi Takahashi, et al.
The study authors conclude that ENA is well tolerated and shows promising efficacy in IDH2-mutated higher-risk myelodysplastic syndromes.
Venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with therapy-related myeloid neoplasms, antecedent myelodysplastic syndromes, or myelodysplastic/myeloproliferative neoplasms.
Vinod Pullarkat, Keith Pratz, Hartmut Dohner, et al.
The study authors conclude that combination of Venetoclax plus azacitidine compared to azacitidine monotherapy resulted in higher CRc rates (Composite complete remission rate (CRc; complete remission [CR] + CR with incomplete hematologic recovery [CRi])) with longer duration of response and median overall survival among treatment-naïve patients with tMN and A-MDS/MPN ineligible for intensive chemotherapy. The safety profile was similar to overall patients with the combination therapy. Outcomes by cytogenetic and molecular risk groups are presented. Clinical trial information: NCT02993523, NCT02203773.
A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies.
Curtis Andrew Lachowiez, Gautam Borthakur, Sanam Loghavi, et al.
The study authors conclude that ivosidenib with venetoclax +/- azacitidine is an effective treatment regimen in patients with IDH1+myeloid malignancies. There is an acceptable and expected toxicity profile with notable efficacy and high rates of MRD-negative CRc in AML. Clinical trial information: NCT03471260
Alexander E. Perl, Richard A. Larson, Nikolai Alexandrovich Podoltsev, et al.
The study authors conclude that a high proportion of gilteritinib-treated R/R FLT3mut+ AML patients who were alive without relapse had received HSCT followed by gilteritinib maintenance. They showed that pre-HSCT remission rates and post-HSCT survival were similar across arms among all transplanted patients in ADMIRAL. Gilteritinib maintenance after HSCT may relate to the low post-HSCT relapse rate in the gilteritinib arm. The safety profile of gilteritinib is stable at 2 years without new or significant safety signals. Clinical trial information: NCT02421939
Prognostic factors of overall (OS) and relapse-free survival (RFS) for patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy (IC): Multivariate analyses from the QUAZAR AML-001 trial of oral azacitidine (Oral-AZA).
Gail J. Roboz, Andrew H. Wei, Farhad Ravandi, et al.
The study authors conclude that treatment with oral azacitidine independently of baseline characteristics reduced the risk of death by 30% and risk of relapse by 43% compared to placebo. Cytogenetic risk at diagnosis, minimal residual disease status, and patient age also independently predicted survival outcomes. Clinical trial information: NCT01757535
A mixed methods study exploring the role of perceived side effects on treatment decision-making in older adults with acute myeloid leukemia (AML).
Dawn Maze, Roland B. Walter, Diana M. Merino, et al.
The study authors conclude that the nature and severity of side effects of AML treatment were perceived to be worse than reality. The authors state, that such an incorrect perception may lead to undertreatment of patients and result in worse outcomes. They recommend more patient education and resources about the lived treatment experience, to enhance understanding and mitigate pre-conceived notions of side effects.
A registry-based, observational safety study of inotuzumab ozogamicin (InO) treatment in patients (pts) with B-cell precursor acute lymphoblastic leukemia (ALL) who proceeded to hematopoietic stem cell transplant (HSCT).
Marcos J.G. De Lima, Partow Kebriaei, Francesco Lanza, et al.
The study authors demonstrate that the Incidence of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after first HSCT in inotuzumab ozogamicin-treated patients with R/R ALL in this study was similar to the 18–19% reported in pooled analyses of 2 clinical trials among inotuzumab ozogamicin-treated patients with R/R ALL and in the INOVATE study. The NRM at 1 y of 21% (23% R/R ALL) is lower than the non-relapse mortality at 1 y of 38% reported in the pooled analyses of R/R ALL inotuzumab ozogamicin recipients.
Measurable residual disease response in acute myeloid leukemia treated with venetoclax and azacitidine.
Keith Pratz, Brian Andrew Jonas, Vinod Pullarkat, et al.
The study authors conclude that patients with best response of composite complete remission (CRc; complete remission [CR] + CR with incomplete hematologic recovery [CRi]) and measurable residual disease response (MRD<10-3) who achieved MRD<10-3 response with venetoclax and azacitidine treatment had longer duration of response, overall and event-free survival than patients who were CRc and measurable residual disease positive. Clinical trial information: NCT02993523
Predictive phosphoproteomic signatures for midostaurin plus chemotherapy response in FLT3 mutant positive acute myeloid leukaemia.
Arran David Dokal, Andrea Arruda, Ryan Smith, et al.
The study authors have identified phospho-signatures with the potential to further stratify FLT3+ AML for midostaurin treatment. They conclude, that the presence of PRKCD signalling components in signatures provides a rationale for midostaurin activity in sensitive cases. Analysis are planned on FLT3 mutant-negative cases to validate the signature in this group.
High dimensional mapping of temporal evolution within the marrow microenvironment in response to FLT3 inhibitor therapy.
Matthew Newman, Sunil K. Joshi, Daniel Bottomly, et al.
The study authors' findings show that primary marrow stroma evolves during gilteritinib treatment. It is also shown that stromal proteins previously reported to promote early resistance to FLT3i are also upregulated during gilteritinib resistance. The heterogeneity of stromal cell isolates detected by mass cytometry highlights the utility of high dimensional tracking of disease course in patients. The authors suggest, that this may enable a better understanding of how the temporal evolution of the marrow microenvironment contributes to the development of resistance to targeted therapies like gilteritinib and other FLT3i over time.